Research programme: tuberculosis vaccine - CEL-SCI

Drug Profile

Research programme: tuberculosis vaccine - CEL-SCI

Alternative Names: LEAPS-based TB vaccine - CEL-SCI

Latest Information Update: 27 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CEL-SCI Corporation
  • Class Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Tuberculosis

Most Recent Events

  • 04 Apr 2013 Discontinued - Preclinical for Tuberculosis (Prevention) in USA (Parenteral)
  • 04 Apr 2013 No development reported - Preclinical for Tuberculosis in USA (Parenteral)
  • 05 Jun 2009 Preclinical trials in Tuberculosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top